License and Development Agreements - Endo License and Development Agreement - Additional Information (Detail) - USD ($) $ in Thousands		1 Months Ended		3 Months Ended		9 Months Ended
	Oct. 26, 2015	Nov. 30, 2015	Oct. 31, 2015	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenue Recognition, Milestone Method [Line Items]
Potential milestone payment receivable upon regulatory approval	$ 50,000		$ 50,000
Milestone payment upon regulatory approval deferred for future revenue recognition		$ 20,000
Patent extension starting period						2020
Patent extension ending period						2027
Royalty payment description						$50 million regulatory approval milestone received in November 2015. Such amount is associated with the Patent Life Extension and is contingently refundable from 2020 to 2027. The $20 million will be earned over the extended 84 month patent period as it is contingently refundable pending a generic product commercially launched in the U.S. during the patent extension period. Sales threshold payments and sales-based royalties will be recognized as they accrue under the terms of the Endo Agreement.
Total rate of reimbursable contractor costs borne						50.00%
Deferred revenue from research and development activities				$ 497	$ 55	$ 501	$ 909
Deferred revenue recognized during the period				6,000		$ 6,000
Endo Agreement [Member]
Revenue Recognition, Milestone Method [Line Items]
Total rate of reimbursable contractor costs borne						50.00%
Reimbursement rate of costs by Endo to the company as per agreement						100.00%
Percentage of credit against potential future milestones						50.00%
Deferred revenue from research and development activities				$ 10	$ 60	$ 10	$ 90